Omega-3 Supplements May Increase Risk of Cognitive Decline, Scientists Warn

#1

Press: Omega-3 Supplements May Increase Risk of Cognitive Decline, Scientists Warn
Paper: The association between omega-3 supplementation and cognitive decline in older adults 2026

Results
Omega-3 supplementation was associated with significantly accelerated cognitive decline, as evidenced by a faster decrease in MMSE scores (β = -0.266, p < 0.001) and a faster increase in both ADAS-Cog13 (β = 0.823, p < 0.001) and CDR-SB scores (β = 0.205, p < 0.001). This association was not mediated by Aβ deposition, tau pathology, or gray matter atrophy. Instead, longitudinal FDG hypometabolism within AD-vulnerable regions served as a significant mediating pathway, accounting for 30.8%, 40.8%, and 19.0% of the total effect on the decline in MMSE, ADAS-Cog13, and CDR-SB, respectively.
Conclusions
Omega-3 supplementation may be associated with accelerated cognitive decline in older adults, potentially through adverse effects on cerebral synaptic function rather than classical AD proteinopathies. These findings challenge the prevailing view of omega-3 as uniformly beneficial and highlight the need for a cautious reassessment of its widespread use for cognitive protection.

ChatGPT:

  • Journal: serious / legitimate (Impact Factor 7.8 and CiteScore 10.0).
  • Research team: real AD-neurology group with relevant publication footprint, but not a world-leading household-name omega-3 trial group.
  • Paper: credible enough to take seriously, but the result should still be treated as an observational signal, not as causal proof.

Main takeaway: interesting signal, but I would not treat it as proof that omega-3 causes cognitive decline.
Reasons:

  1. Confounding by indication is a big concern.
    People who choose omega-3 supplements may already be more worried about memory, have subtle symptoms, have vascular/metabolic issues, or be following advice after health deterioration. The authors say they found “no pre-existing differences in cognitive or FDG-SUVR trajectories before initiation,” but that does not fully eliminate residual confounding.
  2. ADNI is not a general-population cohort.
    ADNI is enriched for people at risk of Alzheimer’s disease, with detailed imaging and cognitive follow-up. Results may not generalize to healthy 40–70-year-olds taking modest fish oil.
  3. “Omega-3 supplementation” is probably heterogeneous.
    Observational datasets often lack precise information on EPA/DHA dose, brand, oxidation quality, duration, adherence, baseline omega-3 index, fish intake, indication, and co-supplements. Those matter a lot.
  4. The result conflicts with much of the broader prior expectation, but not cleanly with RCT evidence.
    Prior randomized evidence has generally been weak/neutral rather than strongly positive. Cochrane found no cognitive benefit for omega-3 in dementia over six months, and a Nutrition Reviews meta-analysis in non-demented adults found no effect on global cognition but a mild memory benefit.
  5. Dietary omega-3 and supplements should be separated.
    Observational studies of dietary fish/omega-3 often look more favorable than supplement trials. A 2023 review found dietary intake and biomarkers were associated with lower dementia/cognitive-decline risk, while supplement RCT evidence remains much less convincing.
1 Like
Predicting Alzheimers & Dementia (and minimizing risk)
#2

On the potential risks of omega-3 supplementation, see also:

1 Like